The Arab Drug Company Statistics

Total Valuation

The Arab Drug Company has a market cap or net worth of EGP 673.62 million. The enterprise value is 1.03 billion.

Market Cap	673.62M
Enterprise Value	1.03B

Important Dates

The next estimated earnings date is Thursday, February 13, 2025.

Earnings Date	Feb 13, 2025
Ex-Dividend Date	Oct 28, 2024

Share Statistics

The Arab Drug Company has 6.00 million shares outstanding. The number of shares has increased by 4.16% in one year.

Current Share Class	n/a
Shares Outstanding	6.00M
Shares Change (YoY)	+4.16%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.55%
Owned by Institutions (%)	n/a
Float	1.51M

Valuation Ratios

The trailing PE ratio is 7.04.

PE Ratio	7.04
Forward PE	n/a
PS Ratio	0.81
PB Ratio	1.56
P/TBV Ratio	1.56
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.11, with an EV/FCF ratio of -9.08.

EV / Earnings	10.74
EV / Sales	1.24
EV / EBITDA	7.11
EV / EBIT	7.92
EV / FCF	-9.08

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.25.

Current Ratio	1.45
Quick Ratio	0.82
Debt / Equity	1.25
Debt / EBITDA	3.74
Debt / FCF	-4.78
Interest Coverage	3.97

Financial Efficiency

Return on equity (ROE) is 26.53% and return on invested capital (ROIC) is 10.17%.

Return on Equity (ROE)	26.53%
Return on Assets (ROA)	8.40%
Return on Capital (ROIC)	10.17%
Revenue Per Employee	720,919
Profits Per Employee	83,338
Employee Count	1,148
Asset Turnover	0.86
Inventory Turnover	2.32

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +55.41% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+55.41%
50-Day Moving Average	101.88
200-Day Moving Average	90.86
Relative Strength Index (RSI)	72.45
Average Volume (20 Days)	2,195

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, The Arab Drug Company had revenue of EGP 827.61 million and earned 95.67 million in profits. Earnings per share was 15.95.

Revenue	827.61M
Gross Profit	294.93M
Operating Income	129.79M
Pretax Income	144.06M
Net Income	95.67M
EBITDA	143.66M
EBIT	129.79M
Earnings Per Share (EPS)	15.95

Full Income Statement

Balance Sheet

The company has 186.60 million in cash and 540.60 million in debt, giving a net cash position of -353.99 million or -59.00 per share.

Cash & Cash Equivalents	186.60M
Total Debt	540.60M
Net Cash	-353.99M
Net Cash Per Share	-59.00
Equity (Book Value)	431.48M
Book Value Per Share	71.91
Working Capital	208.71M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 141.90 million and capital expenditures -255.08 million, giving a free cash flow of -113.18 million.

Operating Cash Flow	141.90M
Capital Expenditures	-255.08M
Free Cash Flow	-113.18M
FCF Per Share	-18.86

Full Cash Flow Statement

Margins

Gross margin is 35.64%, with operating and profit margins of 15.68% and 13.50%.

Gross Margin	35.64%
Operating Margin	15.68%
Pretax Margin	17.41%
Profit Margin	13.50%
EBITDA Margin	17.36%
EBIT Margin	15.68%
FCF Margin	-13.68%

Dividends & Yields

This stock pays an annual dividend of 8.35, which amounts to a dividend yield of 7.44%.

Dividend Per Share	8.35
Dividend Yield	7.44%
Dividend Growth (YoY)	85.56%
Years of Dividend Growth	n/a
Payout Ratio	32.35%
Buyback Yield	-4.16%
Shareholder Yield	3.28%
Earnings Yield	14.20%
FCF Yield	-16.80%

Dividend Details

Stock Splits

The last stock split was on December 30, 2010. It was a forward split with a ratio of 1.5.

Last Split Date	Dec 30, 2010
Split Type	Forward
Split Ratio	1.5

Scores

The Arab Drug Company has an Altman Z-Score of 2.04. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.04
Piotroski F-Score	n/a